secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOGEN INC. (BIIB)
CIK:        0000875045
Form:       8-K
Filed at:   2026-04-06T23:59:59+00:00
Accession:  0000875045-26-000039
Event type: other_material
Sentiment:  negative
Materiality: 0.50
Item codes: 2.02
LLM model:  deepseek-v4-flash:cloud@v2

Biogen warns of $34M pre-tax IPR&D and upfront charge in Q1 2026, impacting EPS by $0.19
--------------------------------------------------------------------------------

- Preliminary estimate: ~$34M pre-tax acquired in-process R&D, upfront and milestone expense for Q1 2026.
- Expected to reduce GAAP and non-GAAP diluted EPS by approximately $0.19 per share.
- Expense includes upfront/milestone payments and premiums on equity securities related to collaboration and license agreements.
- Biogen does not forecast such costs due to uncertainty; final Q1 results not yet finalized and may differ.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/875045/000087504526000039/0000875045-26-000039-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/875045/000087504526000039/biib-20260406.htm
  HTML page:      https://secwatch.observer/filing/0000875045-26-000039

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer